Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2005-10, Vol.19 (10), p.1835-1838
Hauptverfasser: Dengler, J, von Bubnoff, N, Decker, T, Peschel, C, Duyster, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1838
container_issue 10
container_start_page 1835
container_title Leukemia
container_volume 19
creator Dengler, J
von Bubnoff, N
Decker, T
Peschel, C
Duyster, J
description
doi_str_mv 10.1038/sj.leu.2403848
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68617967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188524654</galeid><sourcerecordid>A188524654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-1e832d14528d840ed44e56855e493c1960fe9e205eb0319a2e817292963261583</originalsourceid><addsrcrecordid>eNp1kt-PEyEQxzdG49XTVx8N0eTetgcssPDY6_krucTE6DOh7GxLswsVWE3_BP_ro2lj1dyFhF_zme_MwFTVa4LnBDfyOm3nA0xzysqBySfVjLBW1Jxz8rSaYSnbWijKLqoXKW0xPhjF8-qCcKWwFGxW_V6GceW8yS54FHrkxrL1boV-ubxB0ezMuLeumCL6urgtCsjYnFDae4hrl7KzZhj2KPgyFezGxnqxGupdSC67n4AsDEM6io2hg2gyoAipeBpvAeXwJ-LL6llvhgSvTutl9f3D-2_LT_Xdl4-fl4u72jIpck1ANrQjjFPZSYahYwy4kJwDU40lSuAeFFDMYYUbogwFSVqqqBINFYTL5rK6OuruYvgxQcp6dOmQpvEQpqSFFKRVoi3gu__AbZiiL7lpKhhvCVWYF-rto1TJoiEYy7PU2gygne9DjsYe4uoFkZJTJjgr1PwBqowORmeDh96V-38crv5y2IAZ8iaFYTp8ZnpQ2caQUoRe72J597jXBOtDH-m01aWP9KmPisObU1XTaoTujJ8apwDXRyAVk19DPJf9iOQ99nDQvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220531008</pqid></control><display><type>article</type><title>Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dengler, J ; von Bubnoff, N ; Decker, T ; Peschel, C ; Duyster, J</creator><creatorcontrib>Dengler, J ; von Bubnoff, N ; Decker, T ; Peschel, C ; Duyster, J</creatorcontrib><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2403848</identifier><identifier>PMID: 15990864</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; B-Lymphocytes - drug effects ; B-Lymphocytes - metabolism ; BCR-ABL protein ; Benzamides ; Cancer Research ; Cells, Cultured ; Critical Care Medicine ; Drug Resistance, Neoplasm ; Drug Therapy, Combination ; Everolimus ; Fusion protein ; Fusion Proteins, bcr-abl - genetics ; Fusion Proteins, bcr-abl - metabolism ; Hematology ; Imatinib ; Imatinib Mesylate ; Immunosuppressive Agents - pharmacology ; Intensive ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Mice ; Mutation - genetics ; Oncology ; Piperazines - administration &amp; dosage ; Pyrimidines - administration &amp; dosage ; Rapamycin ; Sirolimus - administration &amp; dosage ; Sirolimus - analogs &amp; derivatives ; Sirolimus - pharmacology ; spotlight-correspondence</subject><ispartof>Leukemia, 2005-10, Vol.19 (10), p.1835-1838</ispartof><rights>Springer Nature Limited 2005</rights><rights>COPYRIGHT 2005 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Oct 2005</rights><rights>Nature Publishing Group 2005.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-1e832d14528d840ed44e56855e493c1960fe9e205eb0319a2e817292963261583</citedby><cites>FETCH-LOGICAL-c486t-1e832d14528d840ed44e56855e493c1960fe9e205eb0319a2e817292963261583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.leu.2403848$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.leu.2403848$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15990864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dengler, J</creatorcontrib><creatorcontrib>von Bubnoff, N</creatorcontrib><creatorcontrib>Decker, T</creatorcontrib><creatorcontrib>Peschel, C</creatorcontrib><creatorcontrib>Duyster, J</creatorcontrib><title>Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - metabolism</subject><subject>BCR-ABL protein</subject><subject>Benzamides</subject><subject>Cancer Research</subject><subject>Cells, Cultured</subject><subject>Critical Care Medicine</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Therapy, Combination</subject><subject>Everolimus</subject><subject>Fusion protein</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Fusion Proteins, bcr-abl - metabolism</subject><subject>Hematology</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mice</subject><subject>Mutation - genetics</subject><subject>Oncology</subject><subject>Piperazines - administration &amp; dosage</subject><subject>Pyrimidines - administration &amp; dosage</subject><subject>Rapamycin</subject><subject>Sirolimus - administration &amp; dosage</subject><subject>Sirolimus - analogs &amp; derivatives</subject><subject>Sirolimus - pharmacology</subject><subject>spotlight-correspondence</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kt-PEyEQxzdG49XTVx8N0eTetgcssPDY6_krucTE6DOh7GxLswsVWE3_BP_ro2lj1dyFhF_zme_MwFTVa4LnBDfyOm3nA0xzysqBySfVjLBW1Jxz8rSaYSnbWijKLqoXKW0xPhjF8-qCcKWwFGxW_V6GceW8yS54FHrkxrL1boV-ubxB0ezMuLeumCL6urgtCsjYnFDae4hrl7KzZhj2KPgyFezGxnqxGupdSC67n4AsDEM6io2hg2gyoAipeBpvAeXwJ-LL6llvhgSvTutl9f3D-2_LT_Xdl4-fl4u72jIpck1ANrQjjFPZSYahYwy4kJwDU40lSuAeFFDMYYUbogwFSVqqqBINFYTL5rK6OuruYvgxQcp6dOmQpvEQpqSFFKRVoi3gu__AbZiiL7lpKhhvCVWYF-rto1TJoiEYy7PU2gygne9DjsYe4uoFkZJTJjgr1PwBqowORmeDh96V-38crv5y2IAZ8iaFYTp8ZnpQ2caQUoRe72J597jXBOtDH-m01aWP9KmPisObU1XTaoTujJ8apwDXRyAVk19DPJf9iOQ99nDQvQ</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Dengler, J</creator><creator>von Bubnoff, N</creator><creator>Decker, T</creator><creator>Peschel, C</creator><creator>Duyster, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib</title><author>Dengler, J ; von Bubnoff, N ; Decker, T ; Peschel, C ; Duyster, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-1e832d14528d840ed44e56855e493c1960fe9e205eb0319a2e817292963261583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - metabolism</topic><topic>BCR-ABL protein</topic><topic>Benzamides</topic><topic>Cancer Research</topic><topic>Cells, Cultured</topic><topic>Critical Care Medicine</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Therapy, Combination</topic><topic>Everolimus</topic><topic>Fusion protein</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Fusion Proteins, bcr-abl - metabolism</topic><topic>Hematology</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mice</topic><topic>Mutation - genetics</topic><topic>Oncology</topic><topic>Piperazines - administration &amp; dosage</topic><topic>Pyrimidines - administration &amp; dosage</topic><topic>Rapamycin</topic><topic>Sirolimus - administration &amp; dosage</topic><topic>Sirolimus - analogs &amp; derivatives</topic><topic>Sirolimus - pharmacology</topic><topic>spotlight-correspondence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dengler, J</creatorcontrib><creatorcontrib>von Bubnoff, N</creatorcontrib><creatorcontrib>Decker, T</creatorcontrib><creatorcontrib>Peschel, C</creatorcontrib><creatorcontrib>Duyster, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dengler, J</au><au>von Bubnoff, N</au><au>Decker, T</au><au>Peschel, C</au><au>Duyster, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>19</volume><issue>10</issue><spage>1835</spage><epage>1838</epage><pages>1835-1838</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>15990864</pmid><doi>10.1038/sj.leu.2403848</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0887-6924
ispartof Leukemia, 2005-10, Vol.19 (10), p.1835-1838
issn 0887-6924
1476-5551
language eng
recordid cdi_proquest_miscellaneous_68617967
source MEDLINE; Springer Nature - Complete Springer Journals; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Animals
Antineoplastic Combined Chemotherapy Protocols - pharmacology
B-Lymphocytes - drug effects
B-Lymphocytes - metabolism
BCR-ABL protein
Benzamides
Cancer Research
Cells, Cultured
Critical Care Medicine
Drug Resistance, Neoplasm
Drug Therapy, Combination
Everolimus
Fusion protein
Fusion Proteins, bcr-abl - genetics
Fusion Proteins, bcr-abl - metabolism
Hematology
Imatinib
Imatinib Mesylate
Immunosuppressive Agents - pharmacology
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Mice
Mutation - genetics
Oncology
Piperazines - administration & dosage
Pyrimidines - administration & dosage
Rapamycin
Sirolimus - administration & dosage
Sirolimus - analogs & derivatives
Sirolimus - pharmacology
spotlight-correspondence
title Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T17%3A03%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20imatinib%20with%20rapamycin%20or%20RAD001%20acts%20synergistically%20only%20in%20Bcr-Abl-positive%20cells%20with%20moderate%20resistance%20to%20imatinib&rft.jtitle=Leukemia&rft.au=Dengler,%20J&rft.date=2005-10-01&rft.volume=19&rft.issue=10&rft.spage=1835&rft.epage=1838&rft.pages=1835-1838&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/sj.leu.2403848&rft_dat=%3Cgale_proqu%3EA188524654%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220531008&rft_id=info:pmid/15990864&rft_galeid=A188524654&rfr_iscdi=true